https://orcid.org/0000-0003-1853-0854
Key Points
NG2 is an epigenetically regulated direct target gene of the leukemic MLL-AF4 fusion protein.
NG2 negatively regulates the expression of the glucocorticoid receptor NR3C1, conferring glucocorticoid resistance to MLLr B-ALL cells.
Subjects:
Lymphoid Neoplasia
Abstract
B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, with long-term overall survival rates of ∼85%. However, B-ALL harboring rearrangements of the MLL gene (also known as KMT2A), referred to as MLLr B-ALL, is common in infants and is associated with poor 5-year survival, relapses, and refractoriness to glucocorticoids (GCs). GCs are an essential part of the treatment backbone for B-ALL, and GC resistance is a major clinical predictor of poor outcome. Elucidating the mechanisms of GC resistance in MLLr B-ALL is, therefore, critical to guide therapeutic strategies that deepen the response after induction therapy. Neuron-glial antigen-2 (NG2) expression is a hallmark of MLLr B-ALL and is minimally expressed in healthy hematopoietic cells. We recently reported that NG2 expression is associated with poor prognosis in MLLr B-ALL. Despite its contribution to MLLr B-ALL pathogenesis, the role of NG2 in MLLr-mediated leukemogenesis/chemoresistance remains elusive. Here, we show that NG2 is an epigenetically regulated direct target gene of the leukemic MLL-ALF transcription elongation factor 4 (AF4) fusion protein. NG2 negatively regulates the expression of the GC receptor nuclear receptor subfamily 3 group C member 1 (NR3C1) and confers GC resistance to MLLr B-ALL cells. Mechanistically, NG2 interacts with FLT3 to render ligand-independent activation of FLT3 signaling (a hallmark of MLLr B-ALL) and downregulation of NR3C1 via activating protein-1 (AP-1)–mediated transrepression. Collectively, our study elucidates the role of NG2 in GC resistance in MLLr B-ALL through FLT3/AP-1–mediated downregulation of NR3C1, providing novel therapeutic avenues for MLLr B-ALL.
Subjects:
Lymphoid Neoplasia
References
1.
Downing
JR
, Wilson
RK
, Zhang
J
, et al. The pediatric cancer genome project
. Nat Genet
. 2012
;44
(6
):619
-622
.2.
Pui
CH
, Yang
JJ
, Hunger
SP
, et al. Childhood acute lymphoblastic leukemia: progress through collaboration
. J Clin Oncol
. 2015
;33
(27
):2938
-2948
.3.
Pui
CH
, Mullighan
CG
, Evans
WE
, Relling
MV
. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
. Blood
. 2012
;120
(6
):1165
-1174
.4.
Meyer
C
, Burmeister
T
, Groger
D
, et al. The MLL recombinome of acute leukemias in 2017
. Leukemia
. 2018
;32
(2
):273
-284
.5.
Biondi
A
, Cimino
G
, Pieters
R
, Pui
CH
. Biological and therapeutic aspects of infant leukemia
. Blood
. 2000
;96
(1
):24
-33
.6.
Sanjuan-Pla
A
, Bueno
C
, Prieto
C
, et al. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia
. Blood
. 2015
;126
(25
):2676
-2685
.7.
Pieters
R
, den Boer
ML
, Durian
M
, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants
. Leukemia
. 1998
;12
(9
):1344
-1348
.8.
Dordelmann
M
, Reiter
A
, Borkhardt
A
, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
. Blood
. 1999
;94
(4
):1209
-1217
.9.
Olivas-Aguirre
M
, Torres-Lopez
L
, Pottosin
I
, Dobrovinskaya
O
. Overcoming glucocorticoid resistance in acute lymphoblastic leukemia: repurposed drugs can improve the protocol
. Front Oncol
. 2021
;11
:617937
.10.
Inaba
H
, Pui
CH
. Glucocorticoid use in acute lymphoblastic leukaemia
. Lancet Oncol
. 2010
;11
(11
):1096
-1106
.11.
Reddy
TE
, Pauli
F
, Sprouse
RO
, et al. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation
. Genome Res
. 2009
;19
(12
):2163
-2171
.12.
Rainer
J
, Lelong
J
, Bindreither
D
, et al. Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia
. Mol Endocrinol
. 2012
;26
(1
):178
-193
.13.
Schmidt
S
, Rainer
J
, Riml
S
, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia
. Blood
. 2006
;107
(5
):2061
-2069
.14.
Petta
I
, Dejager
L
, Ballegeer
M
, et al. The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases
. Microbiol Mol Biol Rev
. 2016
;80
(2
):495
-522
.15.
Evangelisti
C
, Cappellini
A
, Oliveira
M
, et al. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia
. J Cell Physiol
. 2018
;233
(3
):1796
-1811
.16.
Spijkers-Hagelstein
JA
, Pinhancos
SS
, Schneider
P
, Pieters
R
, Stam
RW
. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL
. Leukemia
. 2014
;28
(4
):761
-769
.17.
Gebru
MT
, Atkinson
JM
, Young
MM
, et al. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia
. Blood
. 2020
;136
(9
):1067
-1079
.18.
Small
D
. Targeting FLT3 for the treatment of leukemia
. Semin Hematol
. 2008
;45
(3 Suppl 2
):S17
-S21
.19.
Bueno
C
, Montes
R
, Martin
L
, et al. NG2 antigen is expressed in CD34+ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered?
. Leukemia
. 2008
;22
(8
):1475
-1478
.20.
Menendez
P
, Bueno
C
. Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get?
. Leuk Res
. 2011
;35
(8
):989
-990
.21.
Prieto
C
, Lopez-Millan
B
, Roca-Ho
H
, et al. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL
. Leukemia
. 2018
;32
(3
):633
-644
.22.
Smith
FO
, Rauch
C
, Williams
DE
, et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23
. Blood
. 1996
;87
(3
):1123
-1133
.23.
Behm
FG
, Smith
FO
, Raimondi
SC
, Pui
CH
, Bernstein
ID
. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements
. Blood
. 1996
;87
(3
):1134
-1139
.24.
Wuchter
C
, Harbott
J
, Schoch
C
, et al. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1
. Leukemia
. 2000
;14
(7
):1232
-1238
.25.
Lopez-Millan
B
, Sanchez-Martinez
D
, Roca-Ho
H
, et al. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
. Leukemia
. 2019
;33
(7
):1557
-1569
.26.
Price
MA
, Colvin Wanshura
LE
, Yang
J
, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
. Pigment Cell Melanoma Res
. 2011
;24
(6
):1148
-1157
.27.
Chillon
MC
, Gomez-Casares
MT
, Lopez-Jorge
CE
, et al. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia
. Leukemia
. 2012
;26
(11
):2360
-2366
.28.
Tejedor
JR
, Bueno
C
, Vinyoles
M
, et al. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia
. J Clin Invest
. 2021
;131
(13
):e138833
.29.
Agraz-Doblas
A
, Bueno
C
, Bashford-Rogers
R
, et al. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis
. Haematologica
. 2019
;104
(6
):1176
-1188
.30.
Prieto
C
, Stam
RW
, Agraz-Doblas
A
, et al. Activated KRAS cooperates with MLL-AF4 to promote extramedullary engraftment and migration of cord blood CD34+ HSPC but is insufficient to initiate leukemia
. Cancer Res
. 2016
;76
(8
):2478
-2489
.31.
Castano
J
, Herrero
AB
, Bursen
A
, et al. Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair
. Oncotarget
. 2016
;7
(21
):30440
-30452
.32.
Zanetti
SR
, Velasco-Hernandez
T
, Gutierrez-Aguera
F
, et al. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
. Mol Ther
. 2022
;30
(2
):550
-563
.33.
Bueno
C
, Torres-Ruiz
R
, Velasco-Hernandez
T
, et al. A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features
. Blood
. 2023
;142
(20
):1752
-1756
.34.
Lopez-Millan
B
, Costales
P
, Gutierrez-Aguera
F
, et al. The multi-kinase inhibitor EC-70124 is a promising candidate for the treatment of FLT3-ITD-positive acute myeloid leukemia
. Cancers
. 2022
;14
(6
):1593
.35.
Lopez-Millan
B
, Diaz de la Guardia
R
, Roca-Ho
H
, et al. IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/idarubicin activity in preclinical models of non del5q/5q- AML
. Oncoimmunology
. 2018
;7
(9
):e1477460
.36.
Prieto
C
, Marschalek
R
, Kuhn
A
, Bursen
A
, Bueno
C
, Menendez
P
. The AF4-MLL fusion transiently augments multilineage hematopoietic engraftment but is not sufficient to initiate leukemia in cord blood CD34(+) cells
. Oncotarget
. 2017
;8
(47
):81936
-81941
.37.
Romero-Moya
D
, Bueno
C
, Montes
R
, et al. Cord blood-derived CD34+ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell function
. Haematologica
. 2013
;98
(7
):1022
-1029
.38.
Pieters
R
, Loonen
AH
, Huismans
DR
, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions
. Blood
. 1990
;76
(11
):2327
-2336
.39.
Candelli
T
, Schneider
P
, Garrido Castro
P
, et al. Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics
. Leukemia
. 2022
;36
(1
):58
-67
.40.
O'Byrne
S
, Elliott
N
, Rice
S
, et al. Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs
. Blood
. 2019
;134
(13
):1059
-1071
.41.
Popescu
DM
, Botting
RA
, Stephenson
E
, et al. Decoding human fetal liver haematopoiesis
. Nature
. 2019
;574
(7778
):365
-371
.42.
Godfrey
L
, Crump
NT
, O'Byrne
S
, et al. H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells
. Leukemia
. 2021
;35
(1
):90
-106
.43.
Crump
NT
, Smith
AL
, Godfrey
L
, et al. MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia
. Nat Commun
. 2023
;14
(1
):5208
.44.
Swaminathan
S
, Huang
C
, Geng
H
, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint
. Nat Med
. 2013
;19
(8
):1014
-1022
.45.
Benito
JM
, Godfrey
L
, Kojima
K
, et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199
. Cell Rep
. 2015
;13
(12
):2715
-2727
.46.
Kerry
J
, Godfrey
L
, Repapi
E
, et al. MLL-AF4 spreading identifies binding sites that are distinct from super-enhancers and that govern sensitivity to DOT1L inhibition in leukemia
. Cell Rep
. 2017
;18
(2
):482
-495
.47.
Pan
F
, Sarno
J
, Jeong
J
, et al. Genome editing-induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion
. J Clin Invest
. 2024
;134
(1
):e171030
.48.
Wang
P
, Lin
C
, Smith
ER
, et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II
. Mol Cell Biol
. 2009
;29
(22
):6074
-6085
.49.
Pieters
R
, Schrappe
M
, De Lorenzo
P
, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
. Lancet
. 2007
;370
(9583
):240
-250
.50.
Autry
RJ
, Paugh
SW
, Carter
R
, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia
. Nat Cancer
. 2020
;1
(3
):329
-344
.51.
Song
IH
, Buttgereit
F
. Non-genomic glucocorticoid effects to provide the basis for new drug developments
. Mol Cell Endocrinol
. 2006
;246
(1-2
):142
-146
.52.
Xiao
H
, Ding
Y
, Gao
Y
, et al. Haploinsufficiency of NR3C1 drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage
. Cancer Cell Int
. 2019
;19
:218
.53.
Stam
RW
, den Boer
ML
, Schneider
P
, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
. Blood
. 2005
;106
(7
):2484
-2490
.54.
Chougule
RA
, Shah
K
, Moharram
SA
, Vallon-Christersson
J
, Kazi
JU
. Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
. NPJ Genom Med
. 2019
;4
:7
.55.
Piovan
E
, Yu
J
, Tosello
V
, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia
. Cancer Cell
. 2013
;24
(6
):766
-776
.56.
Spijkers-Hagelstein
JA
, Schneider
P
, Hulleman
E
, et al. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia
. Leukemia
. 2012
;26
(6
):1255
-1265
.57.
Spijkers-Hagelstein
JA
, Mimoso Pinhancos
S
, Schneider
P
, Pieters
R
, Stam
RW
. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia
. Leukemia
. 2013
;27
(5
):1063
-1071
.58.
Garcia-Garcia
J
, Valls-Comamala
V
, Guney
E
, et al. iFrag: a protein-protein interface prediction server based on sequence fragments
. J Mol Biol
. 2017
;429
(3
):382
-389
.59.
Su
YC
, Mattsson
E
, Singh
B
, Jalalvand
F
, Murphy
TF
, Riesbeck
K
. The laminin interactome: a multifactorial laminin-binding strategy by nontypeable Haemophilus influenzae for effective adherence and colonization
. J Infect Dis
. 2019
;220
(6
):1049
-1060
.60.
Greaves
MF
. Infant leukaemia biology, aetiology and treatment
. Leukemia
. 1996
;10
(2
):372
-377
.61.
Pieters
R
. Infant acute lymphoblastic leukemia: lessons learned and future directions
. Curr Hematol Malig Rep
. 2009
;4
(3
):167
-174
.62.
Gardner
RA
, Finney
O
, Annesley
C
, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
. Blood
. 2017
;129
(25
):3322
-3331
.63.
Den Boer
ML
, Harms
DO
, Pieters
R
, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia
. J Clin Oncol
. 2003
;21
(17
):3262
-3268
.64.
van der Sluis
IM
, de Lorenzo
P
, Kotecha
RS
, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia
. N Engl J Med
. 2023
;388
(17
):1572
-1581
.65.
Stam
RW
, Den Boer
ML
, Schneider
P
, et al. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia
. Blood
. 2010
;115
(5
):1018
-1025
.66.
Kino
T
, Su
YA
, Chrousos
GP
. Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology
. Cell Mol Life Sci
. 2009
;66
(21
):3435
-3448
.67.
El Chaer
F
, Keng
M
, Ballen
KK
. MLL-rearranged acute lymphoblastic leukemia
. Curr Hematol Malig Rep
. 2020
;15
(2
):83
-89
.68.
Brown
PA
, Kairalla
JA
, Hilden
JM
, et al. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
. Leukemia
. 2021
;35
(5
):1279
-1290
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal